biostudies-literatureUnknown78(5)Athan EPfizer, Inc.<h4>Background</h4>Respiratory syncytial virus (RSV) and influenza are both typically seasonal diseases, with winter peaks in temperate climates. Coadministration of an RSV vaccine and influenza vaccine could be a benefit, requiring 1 rather than 2 visits to a healthcare provider for individuals receiving both vaccines.<h4>Methods</h4>The primary immunogenicity objective of this phase 3, 1:1 randomized, double-blind, placebo-controlled study in healthy adults aged ≥65 years in Australia was to demonstrate noninferiority of immune responses with coadministration of the stabilized RSV prefusion F protein-based vaccine (RSVpreF) and seasonal inactivated influenza vaccine (SIIV) versus SIIV or RSVpreF administered alone, using a 1.5-fold noninferiority margin (lower bound 95% confidence intervClinical infectious diseases : an official publication of the Infectious Diseases Society of America1360-1368https://www.ebi.ac.uk/biostudies/studies/S-EPMC11093669biostudies-literatureSafety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults.PMC11093669Gilfillan CRyan PStudy C3671006 Investigator GroupCutler MWJiang QAthan ERusso MQuan KLeah AJaques ABaber JTiong FWark PMohan RBird PNeville AMLeelasena IScott RHiew VAnderson ASArgent CGurtman ARook CMorbey CTai SEizenberg PSchmoele-Thoma BVoloshyna OBull SBloch MDe Silva GArya MNelson MLi WLickliter JMcGirr AColquhoun DMurdoch LKalinina EVScott RJCooper DO'Sullivan MDeshmukh SSwanson KAGruber WCGunner EfalseSafety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults.<h4>Background</h4>Respiratory syncytial virus (RSV) and influenza are both typically seasonal diseases, with winter peaks in temperate climates. Coadministration of an RSV vaccine and influenza vaccine could be a benefit, requiring 1 rather than 2 visits to a healthcare provider for individuals receiving both vaccines.<h4>Methods</h4>The primary immunogenicity objective of this phase 3, 1:1 randomized, double-blind, placebo-controlled study in healthy adults aged ≥65 years in Australia was to demonstrate noninferiority of immune responses with coadministration of the stabilized RSV prefusion F protein-based vaccine (RSVpreF) and seasonal inactivated influenza vaccine (SIIV) versus SIIV or RSVpreF administered alone, using a 1.5-fold noninferiority margin (lower bound 95% confidence interv2024-01-01T00:00:00Z2024 May2026-06-02T19:23:07.592Z2026-04-19T03:14:00.962ZS-EPMC110936693799200010.1093/cid/ciad707